Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Perspective Therapeutics (CATX) Research & Development (2016 - 2025)

Perspective Therapeutics (CATX) has disclosed Research & Development for 16 consecutive years, with $32.9 million as the latest value for Q4 2025.

  • Quarterly Research & Development rose 155.56% to $32.9 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $84.2 million through Dec 2025, up 102.26% year-over-year, with the annual reading at $84.2 million for FY2025, 102.26% up from the prior year.
  • Research & Development hit $32.9 million in Q4 2025 for Perspective Therapeutics, up from $20.3 million in the prior quarter.
  • In the past five years, Research & Development ranged from a high of $32.9 million in Q4 2025 to a low of $362000.0 in Q1 2021.
  • Historically, Research & Development has averaged $8.0 million across 5 years, with a median of $5.6 million in 2023.
  • Biggest five-year swings in Research & Development: decreased 12.52% in 2022 and later soared 1412.82% in 2023.
  • Year by year, Research & Development stood at $535000.0 in 2021, then dropped by 12.52% to $468000.0 in 2022, then skyrocketed by 1412.82% to $7.1 million in 2023, then surged by 81.96% to $12.9 million in 2024, then skyrocketed by 155.56% to $32.9 million in 2025.
  • Business Quant data shows Research & Development for CATX at $32.9 million in Q4 2025, $20.3 million in Q3 2025, and $16.6 million in Q2 2025.